Translational Genomics Research Institute (TGen), part of City of Hope, launched JAYseq™, a clinical whole-genome sequencing test for multiple myeloma designed to deliver results in about three days. The test is positioned to streamline myeloma analysis with broader genomic coverage than many targeted assays. TGen said JAYseq is built to support clinical decision-making faster, targeting the workflow needs of multiple myeloma where genomic complexity and treatment selection can depend on timely results. The company’s rollout follows broader growth of rapid sequencing and MRD-adjacent testing programs in oncology. The new launch adds to the competitive set of assay providers seeking speed and clinical utility benchmarks as regulators and payers increasingly scrutinize evidence for genomic tests.